News
Health Canada approves two tests for CML patients
Health Canada has approved the use of two tests designed to detect BCR-ABL transcripts in patients with chronic myeloid leukemia (CML)—the MRDx®...
News
Markers associated with efficacy of malaria vaccine
New research has revealed markers associated with efficacy of the RTS,S/AS01E malaria vaccine (Mosquirix™). The study suggests malaria protection...
News
Diet change can improve survival in obese mice with ALL
Switching to a low-fat diet can improve survival in obese mice with acute lymphoblastic leukemia (ALL), according to new research. Diet-induced...
News
FDA clears instrument for blood typing, screening
The U.S.
News
‘Compelling’ new target found for monocytic AML
Efforts to determine why immune checkpoint blockade is not successful in treating leukemia have resulted in a “compelling” new target to treat...
News
Triplet improves PFS in relapsed/refractory MM
Adding elotuzumab to pomalidomide and low-dose dexamethasone can improve progression-free survival (PFS) in patients with relapsed/refractory...
News
CAR T therapy for MM receives RMAT designation
P-BCMA-101, an autologous chimeric antigen receptor (CAR) T-cell therapy being developed to treat patients with relapsed/refractory multiple...
News
Vaccine inhibits thrombus formation in mice
Investigators designed an antiplatelet vaccine they say could be a novel therapy to prevent recurrent ischemic stroke. The vaccine inhibits...
News
Combo worsens platelet recovery in MDS
Results from the phase 3 SUPPORT trial suggest there is no role for the combination of eltrombopag and azacitidine in patients with intermediate-...
News
Molecule enhances PI activity in multiple myeloma
Researchers say they have identified a new class of protein disulfide isomerase (PDI) inhibitors that sensitize multiple myeloma (MM) cells to...
News
FDA clears portable hematology analyzer
The U.S.
News
Selinexor on fast track for DLBCL
The U.S.
News
Quizartinib receives accelerated assessment for AML
The European Medicines Agency has granted accelerated assessment to the marketing authorization application (MAA) for the FLT3 inhibitor...
News
Sandoz won’t seek U.S. approval for rituximab biosimilar
Sandoz has decided not to pursue U.S. approval for its rituximab product (GP2013), a proposed biosimiliar of Rituxan/Mabthera. GP2013 (Rixathon,...
News
CPI-0610 receives fast track designation for MF
The U.S.